FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Washington,	D.C.	20549
vacinington,	D.O.	_00.0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
- 1	houre per response	. 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Name and Address of Reporting Person* Sawaf Aziz					2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)	(Fir	st) (M E BIOPHARMA	Middle)	NC.	3. Date of Earliest Transaction (Month/Day/Year) 04/02/2024									S S	belov	er (give title v) HIEF FIN		Other (s below)	`	
901 GATEWAY BLVD					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) SOUTH SAN FRANCISCO CA 94080				X Form filed by One Reporting Person Form filed by More than One Reporting Person																
(City)		ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan the satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									n that is inter	nded to					
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or E	3ene	ficial	y Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)						ties cially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	nt (A) or (D)		Price	Report Transa (Instr. 3	ed ction(s) 3 and 4)			(Instr. 4)	
Ordinary Shares 04/02/2					2024	24 A 100,000 ⁽¹⁾ A \$0 338,636		8,636		D										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any				Transaction Code (Instr. 8) Sc Ac (A Di of		osed) r. 3, 4	6. Date Expirat (Month	ion Da	(ear) Securitie Underlyii Derivativ Security 3 and 4)		unt of rities erlying vative rity (In d 4)	str.	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V (A) (D)		Date Expiration Exercisable Date		Title	Amo or Num of Shar	ber									

Explanation of Responses:

1. On April 2, 2024, the reporting person was granted 100,000 RSUs. 37,500 RSUs are subject to service-based vesting conditions and the remaining 62,500 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.

> /s/ Brett A. Grimaud, Attorney-in-Fact

04/04/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.